OMGA Stock Overview
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Omega Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.17 |
| 52 Week High | US$10.09 |
| 52 Week Low | US$1.30 |
| Beta | 1.83 |
| 1 Month Change | -28.15% |
| 3 Month Change | -43.78% |
| 1 Year Change | -73.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.44% |
Recent News & Updates
Recent updates
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Mar 31Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?
Feb 28
Omega Therapeutics: The Next Weight Loss Drug Runner
Jan 16Omega Therapeutics: Starting 2024 With A Bang
Jan 10Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Aug 04Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Jul 14Shareholder Returns
| OMGA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.4% | 0.5% | 2.7% |
| 1Y | -73.6% | 3.4% | 26.0% |
Return vs Industry: OMGA underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: OMGA underperformed the US Market which returned 25% over the past year.
Price Volatility
| OMGA volatility | |
|---|---|
| OMGA Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OMGA's share price has been volatile over the past 3 months.
Volatility Over Time: OMGA's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 94 | Mahesh Karande | omegatherapeutics.com |
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
Omega Therapeutics, Inc. Fundamentals Summary
| OMGA fundamental statistics | |
|---|---|
| Market cap | US$118.31m |
| Earnings (TTM) | -US$92.28m |
| Revenue (TTM) | US$4.94m |
24.2x
P/S Ratio-1.3x
P/E RatioIs OMGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMGA income statement (TTM) | |
|---|---|
| Revenue | US$4.94m |
| Cost of Revenue | US$61.19m |
| Gross Profit | -US$56.25m |
| Other Expenses | US$36.02m |
| Earnings | -US$92.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.67 |
| Gross Margin | -1,139.23% |
| Net Profit Margin | -1,868.73% |
| Debt/Equity Ratio | 43.3% |
How did OMGA perform over the long term?
See historical performance and comparison